ASH 2018 | IDH inhibitors for AML: highlights from ASH 2018

Name: IDH inhibitors for AML: highlights from ASH 2018
Uploaded: 2018-12-18T15:54:06.000Z
Duration: 1 min 25 s
Description: Marina Konopleva, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, gives us an update on the key news for IDH1/2 inhibitors for acute myeloid leukemia (AML) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Marina Konopleva • 18 Dec 2018

ASH 2018

Acute Myeloid Leukemia Leukemia Enasidenib Ivosidenib

Marina Konopleva, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, gives us an update on the key news for IDH1/2 inhibitors for acute myeloid leukemia (AML) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.